Morgan Noble

Mindoula is a next generation population health management company that scales the human connection through technology in addressing mind, body, and life challenges. We identify, engage, and serve populations with behavioral health and medical challenges across the continuum of care. Our adaptive data science approach, multi-platform technology stack, and virtual + in-person care extension teams enable our payer and provider partners to achieve improved outcomes and significantly reduced costs by integrating behavioral, medical, and social determinants of health.

Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.

Filtricine, Inc. is a venture-backed, clinical stage biotech company based in Santa Clara, CA. We are developing a nutrient modulation platform which can identify metabolic vulnerabilities in cancers and exploit those vulnerabilities without the use of drugs.

Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.

Tara Biosystems provides predictive, in vitro human cardiac tissue models for use in drug discovery, safety assessment and translational medicine. Tara Biosystems offers a high-fidelity solution that is based on human stem cell-derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac functionality, including contractile force. The company is dedicated to pioneering predictive cardiac tissue models that enable the faster, safer, and more reliable development of new medicines.

SyntheX expands the druggable proteome using synthetic biology-driven drug discovery platforms. The platforms rely on empirical intracellular selection to discover protein interaction modulators. These can discover compounds that disrupt a specific protein-protein interaction (PPI), or achieve the inverse, and bring an E3 ubiquitin ligase and a neosubstrate of interest together to achieve functional protein degradation. In addition to external discovery collaborations, the platforms have generated an internal oncology pipeline focused on unique mechanisms of action around genetically validated targets.

Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 13 patents and 42 pending, the company introduced its flagship product Pendulum Glucose Control, a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial. Founded in 2013 by a diverse team of scientists with deep microbiology, biochemistry, computational, and clinical expertise, Pendulum has raised $111 million to date from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures and Mayo Clinic among others. Pendulum Therapeutics is headquartered in San Francisco.

Mindoula is a next generation population health management company that scales the human connection through technology in addressing mind, body, and life challenges. We identify, engage, and serve populations with behavioral health and medical challenges across the continuum of care. Our adaptive data science approach, multi-platform technology stack, and virtual + in-person care extension teams enable our payer and provider partners to achieve improved outcomes and significantly reduced costs by integrating behavioral, medical, and social determinants of health.

Privia Health™ is a technology-driven, national physician enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual settings. Its platform is led by industry talent and exceptional physician leadership, and consists of scalable operations and end-to-end, cloud-based technology that reduces unnecessary healthcare costs, achieve better outcomes, and improves the health of patients and the well-being of providers. Through its high-performance physician group (Privia Medical Group), accountable care organization (Privia Quality Network), and population health management programs, Privia works in close partnership with forward-thinking health plans and national payers to better align reimbursements to quality and outcomes. Privia’s proprietary cloud-based technology platform, combined with an innovative approach to patient engagement and physician-driven wellness, focuses on building a better healthcare delivery system and creating a healthier patient population. The company was founded in 2007 and is headquartered in Arlington, Virginia.